Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma

IMM2510 has submitted End-of-Phase 2 (EOP2) communication applications for two Phase III registration clinical trials targeting different types of lung cancer to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study

Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today is pleased to announce preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China.